A little-known Cigna Group subsidiary that sells generic drugs charges prices that skew higher than many competing suppliers, according to a new analysis that raises questions about the company’s role in setting medication prices.

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government programmes, including Medicare and Medicaid, and cash payers to between $149 and $350, down from $500 to $1,000. It also grants them a three-year relief from tariffs.